Triple
T2138579
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Lucentis |
E46708
|
entity |
| Predicate | isRelatedDrug |
P24601
|
FINISHED |
| Object | bevacizumab |
E46087
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: bevacizumab | Statement: [Lucentis, isRelatedDrug, bevacizumab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: bevacizumab Context triple: [Lucentis, isRelatedDrug, bevacizumab]
-
A.
Avastin
chosen
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
B.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Lucentis
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: isRelatedDrug Context triple: [Lucentis, isRelatedDrug, bevacizumab]
-
A.
isProdrugOf
Indicates that one substance is a precursor form that is metabolized in the body to produce the active form of another substance.
-
B.
chemicallyRelatedTo
chosen
Indicates a relationship where two entities are connected through a chemical association, such as sharing structural features, participating in related reactions, or being derivable from one another chemically.
-
C.
protectedDrugClassesInclude
Indicates that the specified set of protected drug classes includes the referenced drug class or classes.
-
D.
isExtendedReleaseFormulationOf
Indicates that one pharmaceutical formulation is an extended-release version of another, designed to release the active ingredient more slowly over time.
-
E.
isRelatedName
Indicates that one name is connected to another through a variant, derivative, or otherwise non-identical but related naming relationship.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a88a174ab48190a5db20c132e5dccf |
completed | March 4, 2026, 7:37 p.m. |
| NER | Named-entity recognition | batch_69abbf74147c81908793c3694894f94a |
completed | March 7, 2026, 6:02 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ae51b1290c8190a08850b428c99a6c |
completed | March 9, 2026, 4:50 a.m. |
| PD | Predicate disambiguation | batch_69abbd96a3b0819081efbfef975e1513 |
completed | March 7, 2026, 5:54 a.m. |
Created at: March 4, 2026, 7:44 p.m.